Phase 2b clinical trial of IMU-856 in celiac disease patients
Latest Information Update: 14 May 2024
At a glance
- Drugs IMU 856 (Primary)
- Indications Coeliac disease; Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 08 May 2024 According to an Immunic media release, the company planning to initiate this trial based on the positive data from the phase 1b clinical trial.
- 10 May 2023 New trial record